FAS-AS1

Summary

FAS-AS1 (FAS antisense RNA 1, HGNC:37128) is a long non-coding RNA gene on chromosome 10q23.31.

Predicted to be involved in regulation of gene expression.

Source: NCBI Gene 100302740 — RefSeq curated summary.

At a glance

• Clinical variants (ClinVar): 1 total — 1 pathogenic

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:37128
Approved symbol	FAS-AS1
Name	FAS antisense RNA 1
Location	10q23.31
Locus type	RNA, long non-coding
Status	Approved
Aliases	SAF
Entrez	100302740
RNAcentral	URS0000759F33 — lncRNA, 1554 nt, 1 organism(s)

Gene structure

Transcript identifiers

Ensembl transcripts: 0

RefSeq mRNA: 0 — MANE Select: None

Canonical transcript exons

None — 0 exons

Expression profiles

Top tissues by expression

0 total, by Bgee expression score (0-100, higher = more expressed):

Regulation

Is transcription factor: no

Literature-anchored findings (GeneRIF, showing 8)

• Here, a culture model of human erythropoiesis revealed that lncRNA Fas-antisense 1 (Fas-AS1 or Saf) was induced during differentiation through the activity of essential erythroid transcription factors GATA-1 and KLF1. (PMID:27067490)
• Down-regulation of SAF with siRNA treatment increases caspase-3/7 activity levels in virus-infected MDMs. This induction of apoptotic caspases occurs exclusively in HIV-1-infected macrophages and not in bystander cells, leading to a significant reduction in HIV-1 replication and overall viral burden in the macrophage culture. (PMID:30918127)
• LncRNA FAS-AS1 inhibits the progression of non-small cell lung cancer through regulating miR-19a-5p. (PMID:32329854)
• Serum long noncoding RNAs FAS-AS1 & PVT1 are novel biomarkers for systemic lupus erythematous. (PMID:32614682)
• Over-Expression of Immune-Related lncRNAs in Inflammatory Demyelinating Polyradiculoneuropathies. (PMID:33057965)
• LncRNA FAS-AS1 upregulated by its genetic variation rs6586163 promotes cell apoptosis in nasopharyngeal carcinoma through regulating mitochondria function and Fas splicing. (PMID:37217794)
• lncRNA FAS-AS1 served as a diagnostic biomarker of end-stage renal disease and mediated vascular calcification via regulating oxidative stress and inflammation. (PMID:38013128)
• METTL14-mediated lncRNA-FAS-AS1 promotes osteoarthritis progression by up-regulating ADAM8. (PMID:39221886)

Cross-species orthologs

0 orthologs

Protein

Protein identifiers

Canonical reviewed UniProt: None (reviewed: )

All UniProt accessions (0):

RefSeq proteins (0): (*=MANE)

Domains & families (InterPro)

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 0 (showing top):

GO Biological Process (0):

GO Molecular Function (0):

GO Cellular Component (0):

Protein interactions and networks

STRING

0 interactions, top by confidence (×1000):

IntAct

0 interactions, top by confidence:

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

1 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	1
Likely pathogenic	0
Uncertain significance	0
Likely benign	0
Benign	0

Top pathogenic / likely-pathogenic (1)

Variant ID	HGVS	Classification
832890	NC_000010.11:g.(?88770845)(89328078_?)del	Pathogenic

SpliceAI

0 predictions. Top by Δscore:

AlphaMissense

0 scored. Top likely-pathogenic:

dbSNP variants (sampled 300 via entrez): RS1002471347 (10:88993865 A>G), RS1002767883 (10:88994713 A>C), RS1003208768 (10:88994397 A>G), RS1004176305 (10:88993236 T>A), RS1004302978 (10:88994014 C>T), RS1005254690 (10:88991948 A>G), RS1005491142 (10:88991026 G>A,C), RS1006611223 (10:88992641 C>T), RS1006678191 (10:88991883 C>T), RS1008954053 (10:88994375 CAT>C), RS1010006732 (10:88992112 G>A), RS1010087286 (10:88993501 A>G), RS1010924533 (10:88992900 C>T), RS1012480834 (10:88992355 A>C,G,T), RS1013027435 (10:88992812 C>T)

Disease associations

OMIM: gene `` | disease phenotypes: MIM:601859

GenCC curated gene-disease

Mondo (1): autoimmune lymphoproliferative syndrome type 1 (MONDO:0011158)

Orphanet (1): Autoimmune lymphoproliferative syndrome (Orphanet:3261)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

0 associations (top):

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

1 total (human), top 1 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Lactic Acid	increases expression	1

Clinical trials (associated diseases)

6 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT01821781	PHASE2	ACTIVE_NOT_RECRUITING	Immune Disorder HSCT Protocol
NCT06730126	PHASE2	RECRUITING	Study of the ITK Inhibitor Soquelitinib to Reduce Lymphoproliferation and Improve Cytopenias in Autoimmune Lymphoproliferative Syndrome (ALPS)-FAS Patients
NCT00392951	PHASE1/PHASE2	COMPLETED	Sirolimus for Autoimmune Disease of Blood Cells
NCT00605657	PHASE1/PHASE2	COMPLETED	Valproic Acid (Depakote[Registered Trademark]) to Treat Autoimmune Lymphoproliferative Syndrome (ALPS)
NCT01672918	Not specified	WITHDRAWN	Fluorodeoxyglucose Imaging Studies to Detect Lymphoma
NCT04902807	Not specified	RECRUITING	Conception of a Diagnosis, Prognosis and Therapeutic Decision Tool for Patients With Autoimmunity and Inflammation